Ontak
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Cancer
Conditions
Metastatic Pancreatic Cancer
Trial Timeline
Oct 1, 2008 → Jan 1, 2012
NCT ID
NCT00726037About Ontak
Ontak is a phase 2 stage product being developed by Eisai for Metastatic Pancreatic Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00726037. Target conditions include Metastatic Pancreatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00726037 | Phase 2 | Terminated |
| NCT00055146 | Phase 2 | Completed |
| NCT00051025 | Phase 2 | Completed |
| NCT00051012 | Approved | Completed |
| NCT00050999 | Approved | Completed |
Competing Products
20 competing products in Metastatic Pancreatic Cancer